ArticleFrontiers in oncology2025

Long-term progression-free survival with first-line pyrotinib monotherapy in a treatment-naïve stage IV NSCLC patient harboring an ERBB2 exon 20 insertion: a case report.

Zhenyu Ke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.